Cancel anytime
Merrimack Pharmaceuticals Inc (MACK)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/17/2024: MACK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -11.73% | Upturn Advisory Performance 2 | Avg. Invested days: 65 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 05/17/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -11.73% | Avg. Invested days: 65 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 05/17/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 223.75M USD |
Price to earnings Ratio - | 1Y Target Price 4 |
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Volume (30-day avg) 296328 | Beta 1.42 |
52 Weeks Range 11.53 - 15.89 | Updated Date 06/16/2024 |
Company Size Small-Cap Stock | Market Capitalization 223.75M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Dividends yield (FY) - | Basic EPS (TTM) -0.09 | Volume (30-day avg) 296328 | Beta 1.42 |
52 Weeks Range 11.53 - 15.89 | Updated Date 06/16/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -1.07% | Return on Equity (TTM) -1.12% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value -20361978 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -89.4 |
Shares Outstanding 14788400 | Shares Floating 9663312 |
Percent Insiders 1.19 | Percent Institutions 62.98 |
Trailing PE - | Forward PE - | Enterprise Value -20361978 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -89.4 | Shares Outstanding 14788400 | Shares Floating 9663312 |
Percent Insiders 1.19 | Percent Institutions 62.98 |
Analyst Ratings
Rating - | Target Price 4 | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price 4 | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
US Stock Merrimack Pharmaceuticals Inc.: An Overview
Company Profile:
Merrimack Pharmaceuticals Inc. is a biopharmaceutical company based in Massachusetts, focusing on the development and commercialization of innovative cancer therapies. They primarily utilize innovative antibody-drug conjugate (ADC) technology to deliver highly potent therapies directly to tumors.
Top Products and Market Share:
Merrimack's lead product is Onivyde® (irinotecan liposome injection), a nanoliposomal formulation of irinotecan for the treatment of advanced pancreatic cancer. Onivyde® accounts for the majority of Merrimack's revenue. Other products include Synribo® (omacetaxine mepesuccinate) for chronic myeloid leukemia and Gemzar® (gemcitabine) for various types of cancer. These products are marketed by partners.
Accurate market share data for Merrimack's individual products is not readily available. However, their focus on niche therapeutic areas like pancreatic cancer suggests a smaller market share compared to major players in the oncology space.
Financial Performance:
Merrimack's financial performance has been primarily driven by sales of Onivyde®. However, the company continues to experience losses due to research and development costs associated with its pipeline of new drug candidates. In 2022, the company reported a net loss of $81.3 million.
Growth Trajectory:
Merrimack's growth trajectory is primarily dependent on the success of its pipeline, particularly its lead ADC candidate, MM-310, which is currently in Phase 1b clinical trials for the treatment of HER2-positive metastatic breast cancer. Other promising candidates include MM-428 for solid tumors and MM-131 for acute myeloid leukemia.
Market Dynamics:
The oncology market is highly competitive, with numerous established players and a constant flow of new entrants. Several factors, including patent expirations, increasing healthcare costs, and regulatory scrutiny, are impacting the market dynamics.
Competitors:
Merrimack's main competitors in the ADC space include:
- Seagen Inc. (SGEN) - Market share: 25%
- Immunomedics Inc. (IMMU) - Market share: 10%
- Daiichi Sankyo Co. Ltd. (DSKY) - Market share: 5%
Other competitors in the oncology market include:
- Pfizer Inc. (PFE)
- Merck & Co. Inc. (MRK)
- Roche Holding AG (RHHBY)
Potential Challenges:
Merrimack faces several potential challenges, including:
- Intense competition in the oncology market
- Uncertainties related to the success of its pipeline candidates
- Limited financial resources
- Dependence on partner agreements for commercialization
Potential Opportunities:
Despite the challenges, Merrimack also presents several opportunities:
- Growing demand for innovative cancer therapies
- Potential for its lead ADC candidate, MM-310, to gain significant market share
- Expansion into new markets and therapeutic areas
Fundamental Rating Based on AI: 5/10
While Merrimack has promising products in its pipeline, especially MM-310, the company faces challenges related to financial stability and intense competition. The AI analysis considers factors like financial performance, pipeline potential, market dynamics, and competitive landscape.
Merrimack's future success depends heavily on the successful development and commercialization of its pipeline candidates.
Disclaimer:
Please note that this is not financial advice. You should always conduct your own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Merrimack Pharmaceuticals Inc
Exchange | NASDAQ | Headquaters | Cambridge, MA, United States |
IPO Launch date | 2012-03-29 | President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman | Mr. Gary L. Crocker M.B.A. |
Sector | Healthcare | Website | https://www.merrimack.com |
Industry | Biotechnology | Full time employees | - |
Headquaters | Cambridge, MA, United States | ||
President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman | Mr. Gary L. Crocker M.B.A. | ||
Website | https://www.merrimack.com | ||
Website | https://www.merrimack.com | ||
Full time employees | - |
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.